drugset

drugset / Trial / NCT03062397

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

NCT03062397 ↗

Phase 2 Unknown 110 enrolled Jeil Pharmaceutical Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Timeline

Start: 2016-12-09
Primary completion: 2020-12
Completion: 2021-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMELPARIB	Small molecule	—	Intravenous

Indications